Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $2.5 million.

  • Cryo Cell International's Free Cash Flow rose 1094.04% to $2.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $6.2 million, marking a year-over-year increase of 10023.55%. This contributed to the annual value of $3.6 million for FY2024, which is 7335.77% up from last year.
  • Cryo Cell International's Free Cash Flow amounted to $2.5 million in Q3 2025, which was up 1094.04% from $644606.0 recorded in Q2 2025.
  • In the past 5 years, Cryo Cell International's Free Cash Flow registered a high of $2.7 million during Q1 2021, and its lowest value of -$8.5 million during Q3 2022.
  • Its 5-year average for Free Cash Flow is $643095.6, with a median of $1.3 million in 2023.
  • In the last 5 years, Cryo Cell International's Free Cash Flow plummeted by 172011.02% in 2022 and then soared by 289134.99% in 2025.
  • Cryo Cell International's Free Cash Flow (Quarter) stood at $1.4 million in 2021, then skyrocketed by 76.92% to $2.5 million in 2022, then crashed by 33.62% to $1.6 million in 2023, then skyrocketed by 31.87% to $2.1 million in 2024, then grew by 16.26% to $2.5 million in 2025.
  • Its Free Cash Flow was $2.5 million in Q3 2025, compared to $644606.0 in Q2 2025 and $892010.0 in Q1 2025.